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AT A GLANCE COMMENTARY  
Scientific Knowledge on the Subject: Streptococcus pneumoniae is the most frequently isolated 
bacterial pathogen in patients with community-acquired pneumonia (CAP). As result of highly 
complex host-pathogen interactions, patients with pneumococcal pneumonia are at increased risk 
of developing cardiovascular complications during and after CAP, including heart failure, 
arrhythmias, strokes, and acute coronary syndromes. Recent studies in mice revealed that S. 
pneumoniae is capable of invading the heart and causing direct cardiac damage during invasive 
pneumococcal disease. Yet, murine pneumococcal pneumonia is poorly representative of human 
disease and whether cardiac invasion occurs during severe pneumonia in humans is unknown. 
Our aim was to determine if pneumococcus 1) invades the myocardium, 2) induces 
cardiomyocyte death, and 3) elicits cardiovascular complications during pneumococcal 
pneumonia, using a validated non-human primate model that closely resembles pneumococcal 
disease in humans.  
What This Study Adds to the Field: This study presents novel evidence that S. pneumoniae can 
invade the heart during severe pneumonia and induces cardiomyocyte death via direct cytotoxic 
effects. These findings could potentially explain the development of short- and long-term cardiac 
complications associated with CAP due to acute cardiomyocyte injury and induction of scar 
formation in the hearts of convalescent non-human primates.  
 
This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org 
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ABSTRACT 
Rationale: Up to one-third of the patients hospitalized with pneumococcal pneumonia 
experience major adverse cardiac events (MACE) during or after pneumonia. In mice, 
Streptococcus pneumoniae can invade the myocardium, induce cardiomyocyte death, and disrupt 
cardiac function following bacteremia, but it is unknown whether the same occurs in humans 
with severe pneumonia. 
Objective: We sought to determine whether S. pneumoniae can 1) translocate the heart, 2) 
induce cardiomyocyte death, 3) cause MACE, and 4) induce cardiac scar formation post-
antibiotic treatment during severe pneumonia using a non-human primates (NHP) model. 
Methods: We examined cardiac tissue from six adult NHP with severe pneumococcal 
pneumonia and three uninfected controls.  Three animals were rescued with antibiotics 
(convalescent animals). Electrocardiogram (ECG), echocardiogram, and serum biomarkers of 
cardiac damage were performed (troponin-T, NT-proBNP and H-FABP). Histologic examination 
included hematoxylin & eosin (H&E) staining, immunofluorescence, immunohistochemistry, 
picosirus red staining and transmission electron microscopy (TEM). Immunoblots were used to 
assess the underlying mechanisms.  
Measurements and Main Results: Non-specific ischemic alterations were detected by ECG and 
echocardiogram. Serum levels of troponin-T and H-FABP levels were increased (p=<0.05) after 
pneumococcal infection in both, acutely-ill and convalescent NHP.  S. pneumoniae was detected 
in the myocardium of all NHP with acute severe pneumonia. Necroptosis and apoptosis were 
detected in myocardium of both, acutely-ill and convalescent NHP. Evidence of cardiac scar 
formation was observed only in convalescent animals by TEM and picosirus red staining.   
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Conclusions: S. pneumoniae invades the myocardium, induces cardiac injury with necroptosis 
and apoptosis, followed by cardiac scarring after antibiotic therapy, in a non-human primate 
model of severe pneumonia. 
 
ABSTRACT WORD COUNT: 250 (Limit 250) 
 
Key words (3-5): Pneumococcal pneumonia, Streptococcus pneumoniae, cardiovascular 
complications, community-acquired pneumonia  
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INTRODUCTION 
Lower respiratory tract infections cost the healthcare system more than 10 billion dollars 
annually in the United States (1, 2).  Community-acquired pneumonia (CAP) and influenza 
infections together are the fourth most prevalent cause of death worldwide (3). The morbidity, 
mortality, and costs associated with CAP have remained unchanged in recent decades, despite 
availability of antibiotic treatments and preventive strategies with immunizations (4, 5).  
Approximately 30% of patients hospitalized with CAP experience major adverse cardiac events 
(MACE) during hospitalization up to ten years post-infection (6-9). Importantly, patients with 
pneumonia and MACE have double the hospital mortality compared to those with pneumonia 
alone (6, 10). MACE in CAP patients include new onset or worsening heart failure, arrhythmias, 
stroke, and acute coronary syndromes (9). Risk factors for a MACE during CAP include 
infection due to S. pneumoniae, older age, severe CAP, hyperlipidemia, obesity, and arterial 
hypertension (6, 8, 11, 12). The pathophysiology of MACE during CAP has been attributed to 
the complex host-pathogen interactions, but the exact mechanisms are not well understood (9, 
13).  
Streptococcus pneumoniae (pneumococcus) is the most frequent bacterial pathogen in 
patients with CAP (14, 15).  Pneumococcal pneumonia has been identified as an independent risk 
factor for the development of MACE during CAP (6, 8, 11, 12, 16). Pneumococcal pneumonia 
can result in cardiovascular complications in 10-30% of patients, affecting mainly those with 
existing cardiovascular diseases (11, 12). Recently, our research group (17, 18) and others (19-
21) have described that the pneumococcus and its virulence factors (e.g., pneumolysin, bacterial 
cell wall, etc.) have direct detrimental effects on the cardiac function of rodents with invasive 
pneumococcal disease (IPD).  We have demonstrated that pneumococcus can invade the heart, 
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and cause small, bacteria-filled lesions within the myocardium (17, 18).  These myocardial 
lesions disrupt cardiac contractility, induce cardiomyocyte death, and subsequently cause de 
novo collagen deposition in mice rescued with antibiotics (convalescent mice) (17, 22). 
Moreover, we have shown that S. pneumoniae is capable of inducing necroptosis, a highly 
proinflammatory programmed cell-death pathway, in lung macrophages during pneumonia (23). 
Pertinent to the present study, necroptosis has been recognized as a key cell death pathway in 
cardiomyocytes during ischemia-reperfusion injury and acute coronary syndromes (24-26).  
Despite epidemiological studies demonstrating pneumococcal infection is an independent 
risk factor for MACE (6-8, 11, 12), it is unknown whether S. pneumoniae can generate direct 
cardiac cytotoxicity (e.g., cell-death), heart failure, clinically relevant arrhythmias, or acute 
coronary syndromes (i.e., MACE) in humans with severe pneumococcal pneumonia (11, 12, 16, 
27). Additionally, the potential underlying mechanisms of MACE during pneumococcal 
pneumonia have been described in rodent models, but it is speculative to extrapolate these 
findings to humans.  To address this knowledge gap, we used a validated non-human primate 
model of severe pneumococcal pneumonia that closely mimics human disease (28) to explore the 
mechanisms of pneumococcal cytotoxicity on cardiomyocytes.  Potential translation of these 
findings to humans includes identification of potential therapeutic targets to prevent MACE, and 
ultimately, improvement in clinical outcomes of patients with CAP.  
 
MATERIALS AND METHODS 
Animal studies were performed at the Texas Biomedical Research Institute (TBRI) in San 
Antonio, Texas. This animal protocol along with all animal experiments were reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC Number 1443PC6) at 
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the TBRI.  
Study Design 
A full description of the NHP model of severe pneumococcal pneumonia has been 
previously published (28). Briefly, six (four males) healthy adult baboons (Papio cynocephalus) 
were bronchoscopically challenged with 10
9
 colony-forming units (CFU) of S. pneumoniae 
serotype 4 (strain TIGR4 (29)). Collection of blood for serum biomarkers and bacterial load 
estimation, acquisition of a 12-lead electrocardiogram (ECG), transthoracic echocardiogram, and 
bronchoalveolar lavage (BAL) were performed before the infection and at the end of the 
experiment prior to euthanasia (28). Continuous 24-hour temperature, heart rate, and 3-lead ECG 
were recorded throughout the experiment via a surgically implanted tether. At the end of the 
experiment, the hearts were harvested and prepared for tissue experiments. Three NHP were 
treated with intravenous ampicillin (80mg/kg/day) for 7 days (i.e., convalescent group) (28). All 
ECGs were read by an expert electrophysiologist (AJR) who was blinded to the experiment 
results. The study design is summarized in the Fig. A of the online supplement. Finally, major 
adverse cardiac events (MACE) were defined as heart failure, arrhythmias or myocardial 
infarctions.  
Study groups  
The cohort was divided in two groups to mimic the pre-antibiotic era and modern era of 
pneumonia patients (28). For the pre-antibiotic era group, we did not treat three NHP with 
antibiotics, and they were called the acute pneumonia and euthanized per protocol, 4-6 days 
post-infection. In contrast, the modern era of pneumonia group, three NHP were rescued with 
antibiotic treatment, and they were called the convalescent pneumonia and euthanized per 
protocol, 9-14 days post infection (28). The end of experiment refers to the moment before 
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euthanasia, that varies for each animal according with the study groups descried above (28). 
Heart tissues of three age- and gender-matched uninfected NHP served as controls (Fig. A of the 
online supplement). 
Transthoracic Echocardiogram Evaluation  
A standard 5-view focused cardiac ultrasound exam was performed using a portable 
ultrasound machine (General Electric Logiq-E Vet) equipped with microconvex (GE model 8C-
RS, 4.0-10.0 MHz) and phased-array (GE model 3S-RS,1.7-4.0 MHz) transducers.  Parasternal 
long- and short-axis, apical and subcostal 4-chambers, and subcostal inferior vena cava (IVC) 
views were obtained to assess the left (LV) and right (RV) ventricular size and function, cardiac 
valves, pericardium, and IVC size and collapsibility.   
Serum Cardiac Biomarkers 
Serum levels of ultra-sensitive Troponin T (Life Diagnostics), Heart Fatty Acid Binding 
Protein (H-FABP, Kamiya Biomedical) and N-terminal pro-brain natriuretic peptide (NT-
proBNP, Neo Scientific) were measured by enzyme-linked immunosorbent assay (ELISA) in 
serum samples pre-infection and at the end of the experiment. Cytokine and chemokine analyses 
were performed using a validated luminex multiplex assay for NHP (30). 
Tissue Staining and Microscopy  
Immunofluorescence (IF) and immunohistochemistry (IHC) were performed in paraffin 
embedded tissues as previously described (18). Primary antibodies used in this study included 
those against serotype 4 capsular polysaccharide antibody (Staten’s Serum Institut); pneumolysin 
(Ply, Santa Cruz Biotechnology), transforming growth factor (TGF)-β (Bio-Rad Laboratories), 
pSMAD3, mixed lineage kinase domain like pseudokinase (MLKL), p-MLKL, Caspase 3 (Cell 
Signaling Technology), receptor-interacting protein kinase 3 (RIP3) (Abcam), and hypoxia 
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inducible factor 1 (HIF1)-α (Bethyl Laboratories).  The secondary antibody used was fluorescein 
isothiocyanate (FITC) labeled goat anti-rabbit antibody (Jackson Immuno Research). Picosirus 
red (Electron Microscopy Sciences), and H&E stained heart sections were scanned with the 
Aperio Scanscope XT (Aperio). IF and IHC images were captured with an Olympus AX70 
microscope. Transmission electron microscopy (TEM) images were obtained with a JEOL 
JEM1230 transmission electron microscope (Peabody).  
Immunoblots 
Hearts were homogenized and processed as previously described (23) with protease 
(Sigma) and phosphatase (Thermo Scientific) inhibitors. 
Statistical Analysis 
All data are presented as medians with interquartile ranges (IQR), or means with standard 
deviations (SD) as appropriate. Pared non-parametric Wilcoxon signed rank test or two-tailed 
Student’s t-test were used to compare data at different time points. All statistical calculations 
were performed using Prism 5 software (GraphPad).  Two tails p-values <0.05 were considered 
statistically significant. 
 
RESULTS 
Six NHP with a median age of 11 (IQR, 10-19) years old, which corresponds to middle-
aged to elderly humans were included in the study. Details about each NHP, and an overview of 
the experiments to develop the severe pneumococcal pneumonia model were previously 
described (28). Demographics and pneumonia severity are presented in Table A of the online 
supplement.  
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Non-invasive Cardiac Evaluation  
Electrocardiography Evaluation 
During baseline evaluation, all animals were in sinus rhythm with normal PR, QT, and 
ST intervals (Table 1, Fig. 1A); P, T and QRS waves resembled their normal morphology in 
humans (Fig. 1A). At the end of the experiment, immediately prior to euthanasia, ECG 
evaluation showed that all 6 NHP had developed sinus tachycardia, diffuse repolarization 
abnormalities represented by diffuse ST segment changes, T waves flattening, and prolongation 
of the corrected QT interval (QTc) (Figs. 1B-E, Table 1). Table 2 presents the individual 
interpretations of the 12-lead ECGs at baseline and at the end of the experiment. No other 
significant alterations were detected in the ECG tracings, even after the cohort was stratified by 
acute or convalescent pneumonia (Table B of the online supplement).  
Echocardiogram Findings  
A qualitative focused cardiac ultrasound (FCU) examination was conducted at baseline 
and at the end of the experiment.  Findings are summarized in Table C in the online 
supplement.  Prior to infection, all 6 NHP had a normal FCU exam. NHP with acute pneumonia 
demonstrated hyperdynamic LV function, moderate tricuspid regurgitation, small pericardial 
effusions, and collapsed IVC’s (central venous pressure (CVP) <5). NHP with convalescent 
pneumonia developed increased LV relative wall thickness and some associated wall motion 
abnormalities (hypokinesis).  
Serum Biomarkers   
Troponin T and H-FABP serum levels were elevated at the end of experiment in all NHP 
compared to baseline levels (median [IQR]; 0.005ng/mL [0.000, 0.025] vs 0.044ng/mL [0.036, 
0.057], p=0.002; 150.8ng/mL [33.25, 281.5] vs 916.9ng/mL [595.8, 1323], p=0.002, 
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respectively) (Figs. 2A and C). When we stratified the cohort by acute or convalescent 
pneumonia (i.e., with and without antibiotic treatment), Troponin T and H-FABP remained 
higher at the end of the experiment in both cohorts, but Troponin T concentration was not 
statistically significant higher than baseline (Figs. 2B and D). In contrast, serum NT-proBNP 
serum levels did not change significantly at the end of the experiment (194.2pg/mL [22.21, 
815.1] vs 141.9pg/mL [39.8, 565.5], p=0.9) (Figs. 2E and F).  
 
Invasive cardiac evaluation 
Detection of Streptococcus pneumoniae 
  We performed immunofluorescent staining of the different parts of the heart in all 
animals and confirmed the invasion of S. pneumoniae in the myocardium (Fig. 3A and B). In 
NHP with acute pneumonia, we observed clusters of pneumococci suggesting that the bacteria 
were capable of replicating within the tissue. In contrast, in NHP with convalescent pneumonia, 
only a few punctate points were observed, representing S. pneumoniae capsule debris (Fig. 3C). 
Quantification of bacteria in heart homogenates confirmed that S. pneumoniae were present in 
NHP with acute pneumonia, and none were detected in those with convalescent pneumonia nor 
in uninfected controls (Fig. B of the online supplement). 
Histopathological Findings 
Tissue sections of the right or left ventricle and the interventricular septum showed 
similar lesions of a focal cardiac injury primarily in perivascular sites of varying extent and 
severity by H&E staining (Fig. C of the online supplement). Affected cardiac myocytes were 
enlarged with a striking increase in eosinophilic staining and were well demarcated from 
adjacent cardiac tissue (Figs. 4A-C). The damage of left ventricles and septum varied in size and 
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infiltration (Fig. C of the online supplement). Varying degenerative and/or necrotic lesions were 
observed in the left ventricle and interventricular septum (Figs. 4A-C). All animals had mild to 
severe myocyte fatty change and vacuolization, focal contraction bands, interstitial edema, focal 
myocytolysis, and scattered inflammatory cells (Figs. 4A and B).  We observed scattered 
myocytolysis in several myocytes (Figs 4A and B), but prominent nuclear pyknosis with 
extensive myocytolysis were apparent in several myocytes (Fig. 4C).  Two NHP exhibited 
additional necrotic lesions defined by nuclear karyolysis and fragmentation, although one site 
had some clumped bacteria (Fig. 4C). 
Using transmission electron microscopy (TEM), we observed that infected NHP 
consistently developed areas of vacuolization with focal contraction bands, and interstitial edema 
in the left ventricle and septum (Fig. 4E and F). Additionally, we identified several areas with 
focal myocytolysis and nuclear pyknosis that corresponded with extensive mitochondrial damage 
characterized by swollen and electron lucent matrices (Fig. 4G). Moreover, the mitochondrial 
cristae were degraded and disorganized, and with decreased density. All these changes were 
evident in both the acute and convalescent pneumonia groups (Fig. 4E-G).  
Cardiac Inflammatory Response 
We observed high concentrations of cytokines and chemokines, including IL-6, TNF-α, 
IL-8, IL-1β, IL-1Rα, and MIP-1α, in homogenized hearts (left ventricle and interventricular 
septum) of all NHP with acute pneumonia (Fig. 5). All three NHP with convalescent pneumonia 
had lower heart concentrations of cytokines and chemokines levels compared to NHP with acute 
pneumonia (Fig. 5A-F). Significantly higher concentrations of IL-6, TNF-α, and IL-1β were seen 
in the left ventricle and interventricular septum of infected NHP vs. uninfected controls (Fig. 5B, 
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D and E).  IL-8 levels were higher in the interventricular septum (Fig. 5C) of NHP with 
convalescent pneumonia vs. uninfected controls.  
Cardiomyocyte Death  
 To test the role of necroptosis in cardiomyocyte death, we stained for RIP3 and pMLKL 
(necroptosis effector) in heart tissues from infected NHP with acute and convalescent pneumonia 
and uninfected controls using IHC staining (Fig. 6A). An increased signal of both RIP3 and 
pMLKL was seen in stained tissues, suggesting necroptosis was taking place throughout the 
myocardium. Increased levels of both RIP3 and pMLKL were confirmed by immunoblot (Fig. 
6B). Additional staining of cardiac tissues with CardioTAC suggested apoptotic cells in the 
myocardium (Fig. D of the Online Supplement). Briefly, CardioTAC labels DNA ends using 
terminal deoxynucleotidyl transferase. In addition, consistent with the presence of apoptotic cells 
in the myocardium, we observed an increase of apoptosis effector caspase-3 mainly in NHP with 
acute pneumonia (Fig. D of the Online Supplement). Collectively these results suggest that S. 
pneumoniae induces programmed death pathways after its invasion of the myocardium.  
Cardiac fibrosis 
 TGF-β in the heart stimulates myofibroblasts to produce collagen to replace dead 
cardiomyocytes (31, 32).  After S. pneumoniae had induced necroptosis in the heart, de novo 
collagen deposition was detected in the left ventricle and septum evident by picosirus red 
staining (Fig. 7A) and TEM (Fig. 7B).  Collagen deposition was seen 9-14 days post-infection in 
convalescent animals.  Additionally, using immunoblot, we identified increased expression of 
pSMAD3 which stimulates collagen production in cardiac myofibroblasts (33).  
Finally, to confirm that cardiac injury and collagen deposition were secondary to S. 
pneumoniae invasion, we explored the HIF1-α pathway that is activated by hypoxia (34). 
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Immunoblots in homogenized hearts of NHP confirmed the HIF1-α pathway was downregulated 
in both acute and convalescent pneumonia groups (Fig. E of the Online Supplement).  
 
DISCUSSION 
The results of our study provide novel evidence that, similar to humans, NHP with severe 
pneumococcal pneumonia develop signs of cardiac injury, including diffuse repolarization 
abnormalities, hyperdynamic left ventricle function, and mild elevations of serum biomarkers 
(i.e., troponin T and H-FABP). Microscopic examination of heart tissues revealed that 
pneumococcus is capable of translocating into the myocardium and induce cardiomyocytes by 
necroptosis and apoptosis. Moreover, we confirmed that heart invasion by S. pneumoniae causes 
severe cardiac injury and local proinflammatory responses independent of antibiotic treatment. 
We provided evidence that NHP with convalescent pneumonia develop interstitial collagen 
deposition (i.e., scar formation) secondary to the TGF-β pathway activation. Our findings are 
novel as they provide translational data highlighting the etiologic role of S. pneumoniae in 
causing MACE in patients with pneumonia. Further, collagen deposition in the myocardium may 
explain the increased long-term risk of MACE after an acute episode of pneumococcal 
pneumonia. 
 Up to 36% of patients hospitalized with CAP develop severe disease that requires 
admission to the intensive care unit (ICU) (35, 36). Due to the severe inflammatory response and 
mitochondrial dysfunction during severe pneumonia, at least 30% of patients develop left 
ventricular dilatation with reduced ejection fraction that usually takes 7-10 days to recover (i.e., 
sepsis-induced cardiomyopathy) (37, 38). In addition, Corrales-Medina et al showed recently in 
a cohort study that 10-30% of adults (without clinical history of cardiac disease) admitted for 
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CAP, developed clinically relevant heart failure, arrhythmias, or acute coronary syndromes, up to 
10 years after hospitalization (6-8). More commonly, up to 59% of patients admitted with sepsis 
develop a cardiac phenomenon called demand ischemia (i.e., mild troponin elevation and 
repolarization abnormalities in absence of myocardial infarction or coronary disease), rather than 
sepsis-induced cardiomyopathy or MACE (39-41). In our study, we found that all six previously 
healthy NHP with pneumococcal pneumonia, developed nonspecific cardiac changes that cannot 
be categorized as MACE but are consistent with what clinicians call demand ischemia. In 
contrast to humans, we were able to perform a detailed ex-vivo examination of the NHP hearts, 
which revealed that S. pneumoniae can invade the heart and induce severe cardiac injury by 
killing cardiomyocytes through necroptosis and apoptosis.  
S. pneumoniae and its virulence factors (e.g., pneumolysin, cell wall, etc.) are cytotoxic 
and capable of inducing inflammation in cardiomyocytes (17, 19, 20). Recently, our research 
group described the novel observation that the pneumococcus is capable of invading the 
myocardium and forming non-purulent, bacteria-filled, microscopic lesions that were associated 
with cardiomyocyte death (apoptosis) and electrocardiographic abnormalities in mice with IPD 
(22). In our experiments with severe pneumococcal pneumonia in NHP, we proved that the 
pneumococcus is capable of invading the bloodstream and translocating the myocardium.  In 
contrast to mice, the hearts of NHP showed S. pneumoniae in clusters, representing active 
replication, that did not form microlesions as previously described in mice (18). This difference 
may be explained by the high bacterial load and longer infection times required to develop 
mature microlesions.  Gilley et al (18) recently described how cardiac invasion by 
pneumococcus occurs as soon as 12 hours after infection, but microlesion formation was 
bacterial load and time-dependent.  Although similar findings have been seen in an IPD model 
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that is not representative of pneumococcal pneumonia in humans, we used an NHP model of 
severe pneumonia that closely mimics the development and pathogenesis of human disease in 
which all the animals develop low-grade bacteremia for a short period (28).   
Cardiomyocytes have been shown to die by apoptosis or necroptosis during injury or 
disease (24-26). Apoptosis is an immunoquiescent form of cell death that requires the activity of 
cysteine proteases known as caspases (42). It has been shown that mice lacking the death 
receptor FAS or mice treated with chemical inhibitors of caspases experience reduced heart 
infarct sizes and less apoptotic positive cells after ischemic and reperfusion injuries (43). 
Opposite of apoptosis, necroptosis, or programmed necrosis, causes severe inflammation and 
tissue damage during disease (44). Necroptosis is modulated by activation of receptor-interacting 
serine/threonine-protein kinase (RIP) 1, RIP3, and the effector molecule MLKL (25, 45). 
Recently, Yin B et al showed that a non-specific inhibitor of RIP1, necrostatin-1, could reduce 
infarct sizes after major ischemic or reperfusion injuries (46). Using an NHP model, we showed 
that cardiomyocytes undergo RIP1-RIP3-MLKL dependent necroptosis and necroptosis 
inhibition with a selective drug has been shown to be protective against S. pneumoniae induced 
cardiac damage as reported by Gonzalez-Juarbe [Companion manuscript]. This finding is 
significant because killing cardiomyocytes and inducing a proinflammatory response may 
contribute to the generation of MACE during pneumococcal pneumonia.  
 Antibiotics have been shown to drastically reduce mortality due to pneumonia and other 
infectious diseases and are the cornerstone of CAP treatment (5). Thus, to mimic the disease 
evolution of CAP in humans, we treated NHP with ampicillin to explore whether antibiotic 
treatment could prevent the development of cardiac injury secondary to S. pneumoniae invasion. 
We revealed that antibiotic treatment did not protect NHP from the development of necroptosis 
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or cardiac injury, and more important, NHP treated with antibiotics formed scars in the heart. 
These findings are consistent with our findings in mice rescued from IPD with antibiotics (17), 
and other experiments in mice with ischemia/reperfusion injury (31). This finding improves our 
understanding of MACE and long-term mortality of CAP patients.  As described by Souders CA 
et al, once cardiomyocytes die, heart tissue is replaced with myofibroblasts that produce an 
extracellular matrix that is rich in collagen and leads to scar formation (47).  Because S. 
pneumoniae is capable of inducing cardiac scar formation and cardiac scars are known to cause 
arrhythmias and heart failure, our findings might explain why MACE occur up to 10 years after 
the acute infection.  
MACE are the result of a complex host-pathogen interaction between underlying co-
morbidities, the infectious pathogen (9), systemic inflammation (48), endothelial dysfunction 
(49), relative prothrombotic state (9), increased cardiac oxygen demand, and low blood oxygen 
levels that place considerable stress on the heart (9). In this study, we have shown that pathogen-
specific mechanisms of S. pneumoniae contribute to the development of cardiac damage during 
pneumococcal pneumonia that could lead to MACE.  
Our study has some important limitations.  First, the experimental design was limited to a 
two-week maximum duration, and findings should not be interpreted as long-term clinical 
outcomes after surviving CAP. Second, the clinical evaluation was limited in capabilities to 
continuously assess oxygenation or hemodynamic parameters that could associated with cardiac 
injury. However, at the end of the experiments, the NHP were not hypotensive to the level 
requiring vasopressor support. Third, we did not specifically exanimated coronary arteries to 
identify thrombus or signs of myocardial infarctions. But, we rollout the clinical diagnosis of 
myocardial infarction according with the current guidelines of the American Heart 
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Association(50).   Finally, the sample size was limited to six NHP with pneumococcal 
pneumonia due to ethical considerations and high costs associated with the implantable 
continuous non-invasive cardiovascular monitoring systems and intensive veterinary medical 
care.  
In summary, severe pneumococcal pneumonia led to development of cardiac injury due 
to direct pathogen invasion, induction of cell death (necroptosis and apoptosis), and subsequent 
cardiac scar formation after antibiotic treatment in a non-human primate model. Further research 
of strategies to mitigate the pathologic mechanisms underlying cardiac injury secondary to 
pneumococcal invasion are needed. 
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FIGURE LEGENDS  
Figure 1. Non-human primates with severe pneumococcal pneumonia developed diffuse 
nonspecific repolarization abnormalities.   12-lead Electrocardiograms (ECGs) were recorded 
at baseline (A) and at the end of the experiment (B-E). At baseline, all animals were in sinus 
rhythm with no repolarization abnormalities (A). After development of pneumococcal 
pneumonia, the ECGs consistently showed sinus tachycardia (B, C), and abnormal repolarization 
(i.e., diffuse T wave and ST segment flattering) (B, C, D, E).  
 
Figure 2. Serum concentrations of cardiac damage biomarkers were elevated in animals 
with acute and convalescent pneumococcal pneumonia. The serum biomarkers of cardiac 
damage, Troponin T, heart fatty acid binding protein (H-FABP) and N-terminal pro-brain 
natriuretic peptide (NT-proBNP), were assessed pre-infection, at days 4-6 for acute group and at 
days 9-14 for convalescent group. Median (n=6) serum concentration of Troponin T (A), H-
FABP (B) and NT-proBNP (C) are shown pre-infection and at the end of the experiment (i.e., 
before euthanasia). To test whether antibiotic treatment could prevent cardiac damage, the cohort 
was stratified into NHP with acute pneumonia (i.e., without antibiotics, n=6) and those 
convalescent pneumonia (i.e., with antibiotics, n=3). Serum levels of Troponin T (B), H-FABP 
(D) and NT-proBNP (F) were assessed for each group pre-infection, at days 4-6 for acute group 
and at days 9-14 for convalescent group.  Values are shown as medians with interquartile ranges 
(IQR).  The paired non-parametric Wilcoxon signed rank test was used to analyze statistical 
differences among the groups. *, p< 0.05; ** p< 0.01; ** p< 0.001; n.s., not significant. 
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Figure 3. Streptococcus pneumoniae translocates into the heart during pneumonia. 
Representative images from left ventricular (A, C) and interventricular septal (B) sections from 
the 6 NHP with pneumococcal pneumonia and 3 uninfected controls (D). S. pneumoniae were 
visualized using immunofluorescence staining with antiserum against serotype 4 
capsular polysaccharide (CPS) (green) and DAPI to reveal nucleated tissue cells. Bacterial 
aggregates with diplococci morphology are seen within the left ventricles and septa of NHP with 
acute pneumonia (A, B). Bacterial cluster conformation indicates active replication (A). Single 
capsule debris were scattered throughout the left ventricles and in the interventricular septa of 
convalescent NHP (C). Pneumococcal capsules were not identified in the hearts of uninfected 
control NHP (D).  
 
Figure 4. Hearts of Non-human primates (NHP) with severe pneumonia developed severe 
cardiac injury with variable pathological characteristics. Representative hematoxylin & eosin 
(H&E) and transmission electron microscopy (TEM) images of heart specimens from NHP with 
acute pneumococcal pneumonia (A, B, E) and convalescent pneumonia (C, F, G), and uninfected 
control NHP (D, H). NHP developed myocyte cytoplasm degenerative changes including fatty 
change, vacuolization, and myofibrillar separation (A, G). Perinuclear and interstitial edema are 
evident, and several myocyte nuclei contain condensed chromation, a necrotic change (A, E).  
Additionally, in the left ventricle myocytes with cytoplasmic changes of contraction bands, focal 
vacuolization, and myocytolysis were identified (B, F). The edematous interstitium contained 
increased small mononuclear cells and some neutrophiles (B). Nuclear edema and karyolyis are 
diffusely evident in cardiomyocytes (B, G). Widespread myocytolysis, contraction bands, 
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striking nuclear pyknosis, and karyolysis are seen in the septum (C, E, F). Finally, mitochondrial 
cristae degradation and edema were consistently observed by TEM (F, G).  
 
Figure 5. Cytokines and chemokines present in homogenized heart of non-human primates 
(NHP) with acute and convalescent pneumococcal pneumonia.  Median concentrations of 
pro-inflammatory cytokines in homogenized left ventricles and interventricular septa of NHP 
with acute and convalescent pneumococcal pneumonia. NHP with acute pneumonia had higher 
concentrations of interleukin (IL)-6 (A), tumor necrosis factor (TNF)-⍺ (B), IL-8 (C), IL-1β, IL-
1R⍺ (E), and macrophage inflammatory protein (MIP)-1⍺ compared to uninfected NHP. 
Convalescent NHP had lower concentrations of cytokines than NHP with acute pneumonia, but 
IL-6(A), TNF⍺ (B), IL-8 (C), and IL-1β (E) persisted at higher levels than uninfected controls. 
Values are shown as medians and interquartile ranges (IQR).  The unpaired nonparametric 
Mann-Whitney U test was used to analyze statistical differences among the groups. All 
comparisons were made against uninfected controls. *, p< 0.05; ** p< 0.01; ** p< 0.001; n.s., 
not significant.  
 
Figure 6. Necroptosis in heart tissue increases after antibiotic treatment. 
Immunohistochemistry (IHC) was used to elucidate the cell pathways involved during cell death 
in NHP with pneumococcal pneumonia. IHC of heart sections stained for receptor-interacting 
protein kinase 3 (RIP3) and phosphorylated mixed lineage kinase domain like pseudokinase 
(pMLKL) (A-B). (C) Immunoblot for RIP3, pMLKL, and SDHA (loading control) in heart tissue 
of infected NHP vs uninfected control. (D) Relative levels of RIP3 and pMLKL protein 
expression determined by comparing the ratio of the detected band versus total protein levels as 
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determined using LI-COR Image Studio Lite. Values are shown as medians and interquartile 
ranges (IQR).  The unpaired nonparametric Mann-Whitney U tests was used to analyze statistical 
differences among the groups. *, P < 0.05; n.s., not significant.  
 
Figure 7: S. pneumoniae induces de novo collagen deposition in non-human primates (NHP) 
with convalescent pneumonia. Representative images of heart sections from the six NHP 
infected with S. pneumoniae and three uninfected controls. Picosirus red was used to identify 
collagen deposition (A). NHP with convalescent pneumonia developed collagen deposition 
throughout the left ventricle and interventricular septum (A). Transmission electron microscopy 
(TEM) was used to confirm collagen deposition (B), identifying areas with conglomerates of 
collagen fibers in NHP that survived the acute pneumonia (B). The upregulation of pSMAD3 in 
convalescent NHP was identified by immunoblots (C) and relative protein levels 
(pSMAD3/SDHA [loading control]) (D) were determined using LI-COR Image Studio Lite. 
Values are shown as medians and interquartile ranges (IQR).  The unpaired nonparametric 
Mann-Whitney U tests was used to analyze statistical differences among the groups. *, P < 0.05; 
n.s., not significant. 
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TABLES 
Table 1. Twelve lead electrocardiogram quantitative analysis of all 6 non-human primates.  
Variable  Baseline  End of Experiment  p value 
Heart rate, bpm  78 (69, 99.5)  122 (102.5, 152)  0.001 
P wave duration, ms  80 (76.5, 87.5)  80 (70, 100)  0.728 
PR interval, ms  140 (121.5, 155)  135 (125, 155)  0.893 
RR interval, ms  769.23 (603.15, 869.74)  491.93 (394.73, 586.36)  0.001 
QRS interval, ms  55 (47.5, 62.5)  55 (50, 63.75)  0.874 
QT interval, ms  310 (287.5, 347.5)  292.50 (281.25, 317.5)  0.323 
Corrected QT, ms  369.76 (341.53, 398.36)  440.20 (398.29, 454.36)  0.001 
ST segment, ms  125 (100, 160)  114 (91.25, 132.5)  0.308 
T wave, ms  125 (120, 140)  130 (125, 143.75)  0.229 
 
 
Table 2. Qualitative individual interpretation of 12-lead ECG’s at baseline and the end of the 
experiment.  
 
  Electrocardiographic Findings 
 Animal  Baseline  End of Experiment 
 
 
Acute 
pneumonia 
1  
Biphasic T waves in lateral 
leads 
 
Inverted T waves inferior and anterolateral 
leads 
2  
No repolarization 
abnormalities 
 Slow ventricular rhythm 
3  
Diffuse ST and T wave 
flattening 
 
Q waves on lateral leads, 
ST segment and T wave flattening in 
inferolateral leads 
 
 
Convalescent 
pneumonia 
4  
No repolarization 
abnormalities 
 Diffuse ST segment and T wave flattening 
5  Short QT segment  Diffuse ST segment and T wave flattening 
6  
No repolarization 
abnormalities 
 
Q waves on lateral leads, 
T wave inversion lateral leads and 
ST segment depression inferior leads 
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Figure 1. Non-human primates with severe pneumococcal pneumonia developed diffuse nonspecific 
repolarization abnormalities.   12-lead Electrocardiograms (ECGs) were recorded at baseline (A) and at the 
end of the experiment (B-E). At baseline, all animals were in sinus rhythm with no repolarization 
abnormalities (A). After development of pneumococcal pneumonia, the ECGs consistently showed sinus 
tachycardia (B, C), and abnormal repolarization (i.e., diffuse T wave and ST segment flattering) (B, C, D, E). 
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Figure 2. Serum concentrations of cardiac damage biomarkers were elevated in animals with acute and 
convalescent pneumococcal pneumonia. The serum biomarkers of cardiac damage, Troponin T, heart fatty 
acid binding protein (H-FABP) and N-terminal pro-brain natriuretic peptide (NT-proBNP), were assessed pre-
infection, at days 4-6 for acute group and at days 9-14 for convalescent group. Median (n=6) serum 
concentration of Troponin T (A), H-FABP (B) and NT-proBNP (C) are shown pre-infection and at the end of 
the experiment (i.e., before euthanasia). To test whether antibiotic treatment could prevent cardiac 
damage, the cohort was stratified into NHP with acute pneumonia (i.e., without antibiotics, n=6) and those 
convalescent pneumonia (i.e., with antibiotics, n=3). Serum levels of Troponin T (B), H-FABP (D) and NT-
proBNP (F) were assessed for each group pre-infection, at days 4-6 for acute group and at days 9-14 for 
convalescent group.  Values are shown as medians with interquartile ranges (IQR).  The paired non-
parametric Wilcoxon signed rank test was used to analyze statistical differences among the groups. *, p< 
0.05; ** p< 0.01; ** p< 0.001; n.s., not significant.  
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Figure 3. Streptococcus pneumoniae translocates into the heart during pneumonia. Representative images 
from left ventricular (A, C) and interventricular septal (B) sections from the 6 NHP with pneumococcal 
pneumonia and 3 uninfected controls (D). S. pneumoniae were visualized using immunofluorescence 
staining with antiserum against serotype 4 capsular polysaccharide (CPS) (green) and DAPI to reveal 
nucleated tissue cells. Bacterial aggregates with diplococci morphology are seen within the left ventricles 
and septa of NHP with acute pneumonia (A, B). Bacterial cluster conformation indicates active replication 
(A). Single capsule debris were scattered throughout the left ventricles and in the interventricular septa of 
convalescent NHP (C). Pneumococcal capsules were not identified in the hearts of uninfected control NHP 
(D).  
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Figure 4. Hearts of Non-human primates (NHP) with severe pneumonia developed severe cardiac injury with 
variable pathological characteristics. Representative hematoxylin & eosin (H&E) and transmission electron 
microscopy (TEM) images of heart specimens from NHP with acute pneumococcal pneumonia (A, B, E) and 
convalescent pneumonia (C, F, G), and uninfected control NHP (D, H). NHP developed myocyte cytoplasm 
degenerative changes including fatty change, vacuolization, and myofibrillar separation (A, G). Perinuclear 
and interstitial edema are evident, and several myocyte nuclei contain condensed chromation, a necrotic 
change (A, E).  Additionally, in the left ventricle myocytes with cytoplasmic changes of contraction bands, 
focal vacuolization, and myocytolysis were identified (B, F). The edematous interstitium contained increased 
small mononuclear cells and some neutrophiles (B). Nuclear edema and karyolyis are diffusely evident in 
cardiomyocytes (B, G). Widespread myocytolysis, contraction bands, striking nuclear pyknosis, and 
karyolysis are seen in the septum (C, E, F). Finally, mitochondrial cristae degradation and edema were 
consistently observed by TEM (F, G).  
 
 
595x368mm (300 x 300 DPI)  
 
 
Page 36 of 5049 AJRCCM Articles in Press. Published on 14-June-2017 as 10.1164/rccm.201701-0104OC 
 Copyright © 2017 by the American Thoracic Society 
  
 
 
Figure 5. Cytokines and chemokines present in homogenized heart of non-human primates (NHP) with acute 
and convalescent pneumococcal pneumonia.  Median concentrations of pro-inflammatory cytokines in 
homogenized left ventricles and interventricular septa of NHP with acute and convalescent pneumococcal 
pneumonia. NHP with acute pneumonia had higher concentrations of interleukin (IL)-6 (A), tumor necrosis 
factor (TNF)-⍺ (B), IL-8 (C), IL-1β, IL-1R⍺ (E), and macrophage inflammatory protein (MIP)-1⍺ compared to 
uninfected NHP. Convalescent NHP had lower concentrations of cytokines than NHP with acute pneumonia, 
but IL-6(A), TNF⍺ (B), IL-8 (C), and IL-1β (E) persisted at higher levels than uninfected controls. Values are 
shown as medians and interquartile ranges (IQR).  The unpaired nonparametric Mann-Whitney U test was 
used to analyze statistical differences among the groups. All comparisons were made against uninfected 
controls. *, p< 0.05; ** p< 0.01; ** p< 0.001; n.s., not significant.  
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Figure 6. Necroptosis in heart tissue increases after antibiotic treatment. Immunohistochemistry (IHC) was 
used to elucidate the cell pathways involved during cell death in NHP with pneumococcal pneumonia. IHC of 
heart sections stained for receptor-interacting protein kinase 3 (RIP3) and phosphorylated mixed lineage 
kinase domain like pseudokinase (pMLKL) (A-B). (C) Immunoblot for RIP3, pMLKL, and SDHA (loading 
control) in heart tissue of infected NHP vs uninfected control. (D) Relative levels of RIP3 and pMLKL protein 
expression determined by comparing the ratio of the detected band versus total protein levels as determined 
using LI-COR Image Studio Lite. Values are shown as medians and interquartile ranges (IQR).  The unpaired 
nonparametric Mann-Whitney U tests was used to analyze statistical differences among the groups. *, P < 
0.05; n.s., not significant.  
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Figure 7: S. pneumoniae induces de novo collagen deposition in non-human primates (NHP) with 
convalescent pneumonia. Representative images of heart sections from the six NHP infected with S. 
pneumoniae and three uninfected controls. Picosirus red was used to identify collagen deposition (A). NHP 
with convalescent pneumonia developed collagen deposition throughout the left ventricle and 
interventricular septum (A). Transmission electron microscopy (TEM) was used to confirm collagen 
deposition (B), identifying areas with conglomerates of collagen fibers in NHP that survived the acute 
pneumonia (B). The upregulation of pSMAD3 in convalescent NHP was identified by immunoblots (C) and 
relative protein levels (pSMAD3/SDHA [loading control]) (D) were determined using LI-COR Image Studio 
Lite. Values are shown as medians and interquartile ranges (IQR).  The unpaired nonparametric Mann-
Whitney U tests was used to analyze statistical differences among the groups. *, P < 0.05; n.s., not 
significant.  
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SUPPLEMENTARY TABLES 
Table A. Demographics and Clinical Characteristics of Non-Human Primates with confirmed 
pneumococcal pneumonia  
 
 
 
Variables 
 
Acute   
n= 3 
 
Convalescent  
n= 3 
 
 
p 
value 
 
      Age, years, mean (SD)
 
 
12.3 (4.0) 
 
 17.3 (5.6) 
 
0.28 
Male, n (%)
 
3 (100) 1 (33) 0.41 
 
Systemic inflammatory response (SIRS) parameters, mean (SD)   
Heart rate, beats/min 144.7 (8.3) 139.3 (7.6) 0.45 
Temperature, 
o
C 102.7 (1.5) 102.3 (1.5) 0.80 
White blood cells, thousands/mm
3
 5.7 (2.1) 4.9 (1.2) 0.58 
Bands, % 4.0 (4.3) 2 (3.4) 0.56 
Bacteremia, Log10 (CFU/ml)  3.9 (0.7) 4.6 (0.7) 0.27 
 
Pneumonia severity, mean (SD) 
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Table B. 12 lead electrocardiograms characteristics in all the baboons. 
 Baseline  End of the experiment 
 
Variable 
 
Acute 
 
Convalescent 
p 
value 
 
 
Acute 
 
Convalescent 
p 
value 
 
Heart rate, bpm 
 
95 ± 18.9 
 
75.1 ± 9.2 
 
0.01 
 
 
134.8 ±22.2 
 
104.7 ± 45. 
 
0.08 
P wave duration, 
ms 
82.2 ± 6.7 77.5 ± 17.6 0.40  93.8 ±25.1 79.1 ± 15.1 0.14 
PR interval, ms 139.2 ± 12.2 136.7 ± 25.3 0.76  137.2 ±13.9 126.5 ± 47.9 0.51 
R-R interval, ms 
654.3 ± 
160.2 
808.2 ± 89.3 0.01  456.4 ±80.3 848.4 ±856.4 0.19 
R-R interval, sec 0.6 ± 0.2 0.8 ± 0.1 0.01  0.5 ± 0.1 0.8 ± 0.9 0.19 
QRS interval, ms 47.2 ± 7.9 62.8± 12.2 0.02  51.1 ± 7.8 99.1 ±136.6 0.27 
QT interval, ms 317.7 ±40.4 307 ± 63.6 0.64  283.7 ± 18.8 323.5 ± 41.4 0.02 
Corrected QT, ms 395.1 ± 20.5 342.2 ±67.8 0.02  417.9 ± 37.6 440.8 ±73.1 0.44 
ST segment, ms 139.4 ± 51.5 119.5 ± 51.0 0.39  101.2 ±17.2 129.7 ±23.2 0.01 
T wave, ms 131.1 ±14.7 124.5 ±19.3 0.39  131.8 ±11.9 134.3 ±13.2 0.69 
Bpm: beats per minute; sec: seconds; ms: milliseconds 
 
 
 
Neutrophils, %  66.6 (13.3) 87 (2.0) 0.06 
      Lymphocytes, thousands/mm
3 
1.3 (0.3) 0.9 (0.4) 0.23 
Hemoglobin, gr/dL  11.7 (0.8) 10.5 (0.7) 0.15 
Platelets, thousands/mm
3
 242.3 (52.5) 264.3 (27.5) 0.55 
Creatinine, md/dL 0.7 (0.1) 0.7 (0.2) 0.99 
Blood urea nitrogen, mg/dL 7.6 (2.8) 12.3 (4.9) 0.23 
Glucose, md/dL 88.6 (9.5) 110.0 (20.3) 0.17 
Aspartate transaminase, U/L 41.0 (12.7) 36.0 (12.7) 0.65 
Alkaline phosphatase, U/L 447.7 (214.2) 336.3 (40.6) 0.42 
Albumin, gr/dL 2.7 (0.2) 2.7 (0.1) 0.74 
pH 7.5 (0.02) 7.5 (0.06) 0.61 
Lactate, mM/L 1.8 (0.2) 2.1 (0.2) 0.16 
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Table C. Summary findings of the focused cardiac ultrasound (FCU) examination conducted at 
baseline and at the end of the experiment.  
GROUP BABOON ORGAN BASELINE END OF THE 
EXPERIMENT 
 
 
 
 
 
 
 
 
 
 
 
 
Acute 
pneumonia 
1 Left Ventricular 
Function 
Normal LVSF  (50-
55%) 
Normal LVSF (50-55%) 
Right Ventricular 
Function 
Normal RVSF Normal RVSF 
Valves Normal Normal 
Pericardium Normal Normal 
IVC Normal CVP (5mm 
Hg) 
Low CVP (<5mm Hg) 
2  Left Ventricular 
Function 
Normal LVSF No images due to 
sudden death 
Right Ventricular 
Function 
Normal RVSF  
Valves Normal  
Pericardium Normal  
IVC Normal  
3 Left Ventricular 
Function 
Normal LVSF (50-
55%) 
Hyperdynamic LVSF 
(65-70%) 
Right Ventricular 
Function 
Normal RVSF Normal RVSF 
Valves Normal Moderate tricuspid 
regurgitation 
Pericardium Normal Small pericardial 
effusion 
IVC Normal Collapsed (CVP <5)  
0.60/0.25 
Comments  Lungs of this animal had 
severe pneumonia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Left Ventricular 
Function 
Normal LVSF (50-
55%) 
Normal LVSF (50-55%) 
Right Ventricular 
Function 
Normal RVSF Normal LVSF & RVSF, 
NL RV and LV size, No 
WMAs 
Valves Normal Moderate TR 
Pericardium Normal Normal 
IVC Normal Collapsed (CVP <5) 
Comments  Bilateral 
hydronephrosis.  RLL 
pneumonia looks better 
than Baboon #4 prior to 
euthanasia, but probably 
similar to baboon #3 
(moderate severity).  No 
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 Convalescent 
pneumonia  
pleural effusions. 
5 Left Ventricular 
Function 
Normal LVSF (50-
55%) 
Normal LVSF (50-55%), 
Significantly increase 
circumferential LV 
relative wall thickness 
(greater in inferior wall), 
mild inferior wall 
hypokinesis,  
Right Ventricular 
Function 
Normal RVSF Reduced RVSF, 
increased RV relative 
wall thickness, 
paradoxical septal 
motion 
Valves Normal Possible anterior mitral 
valve leaflet vegetation 
Pericardium Normal Small, complex 
pericardial effusion with 
septations  
IVC Normal Dilated, non-collapsible 
(CVP>15) 
Comments  Overall this was the 
sickest of the baboons 
that we have imaged.   
6 Left Ventricular 
Function 
Normal LVSF (50-
55%) 
Normal LVSF (50-55%), 
Mild dilation of LV 
chamber, Significant 
increased 
circumferential LV 
relative wall thickness, 
no wall motion 
abnormalities 
Right Ventricular 
Function 
Normal RVSF Reduced RVSF, 
moderate RV chamber 
dilation, increased RV 
relative wall thickness 
Valves Normal Normal 
Pericardium Normal No pericardial effusion 
IVC Collapsed (CVP <5) Collapsed (CVP <5) 
Comments  Large left lower back 
abscess (vs. hematoma) 
around site of 
insertion of monitoring 
leads. 
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SUPPLEMENTARY FIGURE LEGENDS 
Figure A. Study design. Methods used for the non-invasively assessment of Major 
Cardiovascular Event (MACE) and invasive assessment of cardiac injury.  
 
Figure B. Heart bacterial load. S. pneumoniae invades and replicates within the heart of NHP 
with acute severe pneumococcal pneumonia (i.e., without antibiotic treatment).  
 
Figure C. S. pneumoniae induces cardiac injury with different sizes and characteristics.  
The variability in the size of the focal myocardial lesions that localize in perivascular sites is 
seen (A and B).   The enlarged eosinophilic-stained myocytes in the lesions are sharply separated 
from surrounding myocardial tissue (A and B).  H&E, 4x and 10x magnification, respectively.  
 
Figure D. Cardiomyocytes died by apoptosis and necroptosis. CardioTAC staining was used 
to explore the presence of apoptosis in heart of NHP with severe pneumococcal pneumonia (A). 
Immunoblot for cleaved Caspase 3 and Actin (loading control) in heart tissue of infected NHP vs 
uninfected controls confirmed activation of apoptosis. 
 
Figure E. Ischemia was not detected in the heart of NHP with severe pneumonia. Hypoxia 
was not detected using immunoblot for hypoxia inducible factor 1 (HIF1)-α and SDHA (loading 
control) in the heart of NHP with severe pneumococcal pneumonia independent of antibiotic 
treatment (acute vs. convalescent pneumonia).  
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Figure A. Study design. Methods used for the non-invasively assessment of Major Cardiovascular Event 
(MACE) and invasive assessment of cardiac injury.  
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Figure B. Heart bacterial load. S. pneumoniae invades and replicates within the heart of NHP with acute 
severe pneumococcal pneumonia (i.e., without antibiotic treatment).  
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Figure C. S. pneumoniae induces cardiac injury with different sizes and characteristics.  The variability in the 
size of the focal myocardial lesions that localize in perivascular sites is seen (A and B).   The enlarged 
eosinophilic-stained myocytes in the lesions are sharply separated from surrounding myocardial tissue (A 
and B).  H&E, 4x and 10x magnification, respectively.  
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Figure D. Cardiomyocytes died by apoptosis and necroptosis. CardioTAC staining was used to explore the 
presence of apoptosis in heart of NHP with severe pneumococcal pneumonia (A). Immunoblot for cleaved 
Caspase 3 and Actin (loading control) in heart tissue of infected NHP vs uninfected controls confirmed 
activation of apoptosis.  
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Figure E. Ischemia was not detected in the heart of NHP with severe pneumonia. Hypoxia was not detected 
using immunoblot for hypoxia inducible factor 1 (HIF1)-α and SDHA (loading control) in the heart of NHP 
with severe pneumococcal pneumonia independent of antibiotic treatment (acute vs. convalescent 
pneumonia).  
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